The multifaceted role of MUC1 in tumor therapy resistance.

Weiqiu Jin, Mengwei Zhang, Changzi Dong, Lei Huang, Qingquan Luo

Clinical and experimental medicine 2023 Sep

filter terms:

Tumor therapeutic resistances are frequently linked to the recurrence and poor prognosis of cancers and have been a key bottleneck in clinical tumor treatment. Mucin1 (MUC1), a heterodimeric transmembrane glycoprotein, exhibits abnormally overexpression in a variety of human tumors and has been confirmed to be related to the formation of therapeutic resistance. In this review, the multifaceted roles of MUC1 in tumor therapy resistance are summarized from aspects of pan-cancer principles shared among therapies and individual mechanisms dependent on different therapies. Concretely, the common mechanisms of therapy resistance across cancers include interfering with gene expression, promoting genome instability, modifying tumor microenvironment, enhancing cancer heterogeneity and stemness, and activating evasion and metastasis. Moreover, the individual mechanisms of therapy resistance in chemotherapy, radiotherapy, and biotherapy are introduced. Last but not least, MUC1-involved therapy resistance in different types of cancers and MUC1-related clinical trials are summarized. © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Citation

Weiqiu Jin, Mengwei Zhang, Changzi Dong, Lei Huang, Qingquan Luo. The multifaceted role of MUC1 in tumor therapy resistance. Clinical and experimental medicine. 2023 Sep;23(5):1441-1474